Tri-Institutional Therapeutics Discovery Institute

Recent papers from Tri-Institutional Therapeutics Discovery Institute

1. Structure–Activity Relationship Study of Antimalarial Asparagine-Derived Proteasome InhibitorsACS Omega · 2026
2. Entropy quantum computing for fixed-backbone protein designScientific Reports · 2026
3. Label-Free High-Throughput Screening of CYP3A4 Inhibitors Using Acoustic Ejection Mass SpectrometryAnalytical Chemistry · 2026
4. Amine-to-Halogen Exchange Enables an Amine–Acid EtherificationJACS Au · 2026
5. CAR-T Targeting of Mutant Calreticulin Establishes a Potentially Curative Stem Cell-Directed Therapy for Myeloproliferative Neoplasms2026
6. Next-generation anti-DLL3 radiopharmaceuticals targeting high-grade neuroendocrine lung and prostate cancersProceedings of the National Academy of Sciences · 2026
7. Relative BAT: An Automated Tool for Relative Binding Free Energy Calculations by the Separated Topologies ApproachJournal of Chemical Information and Modeling · 2025
8. Discovery, Optimization, and Evaluation of Non-Nucleoside SARS-CoV-2 NSP14 InhibitorsJournal of Medicinal Chemistry · 2025
9. Discovery of Novel Isofunctional SARS-CoV-2 NSP14 RNA Cap Methyltransferase Inhibitors by Structure-Based Virtual ScreeningACS Medicinal Chemistry Letters · 2025
10. A human antibody specific for SIRPα reprograms macrophages and promotes antibody mediated anti-cancer activityPLoS ONE · 2025
11. The critical role of PSAC channel in malaria parasite survival is driven home by phenotypic screening under relevant nutrient levelsCell chemical biology · 2025
12. Identification of B cell antigens in solid cancer: initial insights and functional implicationsFrontiers in Immunology · 2025
13. Comparing Molecules Generated by MMPDB and REINVENT4 with Ideas from Drug Discovery Design TeamsJournal of Chemical Information and Modeling · 2025
14. A potent and selective TNKS2 inhibitor for tumor-selective WNT suppression2025
15. IL13Rα2-Targeting Antibodies for Immuno-PET in Solid MalignanciesJournal of Nuclear Medicine · 2025
16. IL-33-activated ILC2s induce tertiary lymphoid structures in pancreatic cancerNature · 2025
17. Vectorized Human Antibody-Mediated Anti-Eosinophil Gene TherapyHuman Gene Therapy · 2024
18. ROS‐Activatable Prodrug of Doxazolidine as Novel Cancer Therapy ParadigmAdvanced Therapeutics · 2024
19. BAT2: an Open-Source Tool for Flexible, Automated, and Low Cost Absolute Binding Free Energy CalculationsJournal of Chemical Theory and Computation · 2024
20. A targetable secreted neural protein drives pancreatic cancer metastatic colonization and HIF1a nuclear retentionCancer Discovery · 2024